CAMLIN FINE SCIENCES LTD.

Camlin Fine Sciences Ltd announced that promoter Ashish Subhash Dandekar has created an encumbrance on 1,57,60,000 equity shares, representing 8.20% of the total share capital. This pledge, executed on October 27, 2026, is for additional margin to cover a shortfall in security cover related to financial assistance obtained. The shares were pledged with Aditya Birla Capital Limited. In a separate transaction on the same date, 1,63,10,000 shares (8.49% of total capital) were pledged with SKS Fincap Private Limited. Mr. Dandekar's total promoter shareholding is 10.30% (1,97,78,510 shares). The encumbered shares represent 82.46% of his total promoter holding.

Camlin Fine Sciences Ltd has announced the completion of tenure for its Independent Director, Mr. Pradip Kanakia (DIN: 00770347). His term as an Independent Director concluded on Sunday, October 18, 2026, after serving five consecutive years. The company expressed its gratitude for his contributions and guidance during his tenure. This intimation is in compliance with SEBI Listing Regulations.

Camlin Fine Sciences Ltd has announced the closure of its trading window for dealing in the company's shares. This closure is effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the Un-audited Standalone and Consolidated Financial Results for the quarter and half-year ended September 30, 2026. The closure applies to Designated Persons and their immediate relatives, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The specific date for the Board Meeting to consider these financial results will be communicated later.

Camlin Fine Sciences Ltd has announced the appointment of Mr. Atul Pradhan as an Additional Non-Executive Independent Director. The appointment, approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee, is effective from September 11, 2026, for an initial term of five years, subject to shareholder approval. Mr. Pradhan brings extensive experience in corporate advisory, management consulting (formerly with KPMG India), and board governance across various sectors. He is not related to any existing directors and is not debarred from holding a directorship.

Camlin Fine Sciences Ltd announced the Un-audited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026. The Board of Directors approved these results, which were recommended by the Audit Committee. The results, along with the Limited Review Reports from the Statutory Auditors, will be published in newspapers and uploaded on the company's website. The board meeting commenced at 02:00 p.m. (IST) and concluded at 03:35 p.m. (IST).

Camlin Fine Sciences' consolidated (primary) Q1 FY27 loss widened to ₹33.62 Cr from ₹10.68 Cr a year ago — reported PAT down roughly 215% YoY; adjusted for this quarter's ₹11.11 Cr exceptional charge, the underlying loss was still up ~111% YoY to ₹22.51 Cr. Standalone lost a smaller ₹12.31 Cr, more than 2x divergence from consolidated — the gap is mostly subsidiaries' operating losses, the exceptional charge (booked only at the consolidated level) and a ₹1.83 Cr discontinued-operations loss that doesn't touch the standalone P&L. Consolidated revenue from operations was ₹519.88 Cr, up 22.7% YoY (against our tracked year-ago base of ₹423.55 Cr) and 22.4% QoQ against this filing's own recast Q4 FY26 column of ₹424.81 Cr. No management press release accompanied this filing, and there is no formal quarterly Street consensus available for Camlin Fine, so vs-Street reads unknown — Trendlyne's two-analyst FY27 consensus pegs full-year revenue near ₹2,361 Cr and EPS at ₹7.65, both now resting on a much bigger back-half recovery after this loss-making Q1. The loss was a margin story, not a revenue miss. Consolidated operating EBITDA (segment results before exceptional items) fell to ₹17.64 Cr — a 3.39% margin — from ₹21.19 Cr (4.99%) in Q4 FY26 and ₹20.29 Cr (4.98%) in Q1 FY26, even as revenue grew double digits both sequentially and YoY, meaning input and employee costs outpaced the topline. The ₹11.11 Cr exceptional charge splits into a ₹10.88 Cr shortfall on the insurance claim settlement for the February 2026 fire at CFS Do Brasil's blending unit (Note 7) plus ₹0.23 Cr unallocated — a real cash item, not a paper adjustment. By segment: Specialty Ingredients (the largest) grew revenue 36.7% YoY to ₹401.32 Cr but its segment result fell 15.1% YoY to ₹25.47 Cr; Aroma revenue rose 36.6% YoY to ₹77.41 Cr — consistent with management's guided vanillin volume/realisation pickup — yet stayed loss-making at -₹3.38 Cr, though narrower than Q4's -₹8.80 Cr; Performance Chemicals & Others swung from a ₹3.65 Cr profit in Q4 to a -₹4.44 Cr loss, still better than the -₹7.65 Cr loss a year ago. Against the FY27 guidance from the May 2026 call — revenue of ₹2,200-2,400 Cr and EBITDA margins of 12-14% — this quarter's 3.39% margin is a sharp miss, and the ₹519.88 Cr Q1 run-rate needs to keep accelerating to reach the guided revenue band; the ₹1,400 Cr FY27 Blends target (within Specialty Ingredients) can't be verified from this filing's segment cuts. Two corporate developments this quarter: the Company completed its open offer for Vinpai S.A. minority shareholders on July 6, 2026, lifting its stake to 95.41% from 83.82% for ₹19.46 Cr; and the Board held the 33rd AGM and filed the FY26 BRSR report alongside these results. Management separately noted a second fire (Dahej Diphenol unit, May 23, 2026) is expected to be fully insurance-covered with no residual loss (Note 9) — worth checking given the ₹10.88 Cr shortfall just booked on the earlier Brazil claim. This sets up a Q2 FY27 where the key questions are whether Aroma's revenue growth converts to segment profit and whether the EBITDA margin starts closing the gap to the 12-14% guided range.

Camlin Fine Sciences Ltd has announced that its Board of Directors will convene on August 11, 2026. The primary agenda item for this meeting is to consider and approve the Un-audited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026. In line with SEBI regulations, the company also informed about the closure of the trading window for its equity shares, effective from July 1, 2026, until 48 hours after the public announcement of the financial results.

Camlin Fine Sciences Ltd announced that promoter Ashish Subhash Dandekar has released a pledge on 1,49,50,000 equity shares, representing 7.78% of the total share capital. This release follows the repayment of borrowings by the Target Company. The promoter's total holding in the company is 10.30% (1,97,78,510 shares), with 4,000 shares (0.00%) still encumbered. The disclosure was made on July 28, 2026, in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Camlin Fine Sciences Ltd is notifying its shareholders about the upcoming 33rd Annual General Meeting (AGM) scheduled for August 11, 2026, at 10:00 AM IST. The meeting will be conducted via Video Conferencing (VC) or Other Audio Visual Means (OAVM). For members who have not registered their email addresses, a physical letter containing a web-link to the Annual Report for FY 2025-26 is being dispatched. The company also reminds shareholders holding physical securities to update their KYC details as per SEBI regulations, including PAN, address, mobile number, bank details, and nomination choice, to ensure eligibility for payments like dividends. The Annual Report is also available on the company's website.

Camlin Fine Sciences Ltd has announced its 33rd Annual General Meeting (AGM) scheduled for Tuesday, August 11, 2026, at 10:00 a.m. IST. The meeting will be conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM). The company has also submitted its Annual Report for the Financial Year 2025-26, along with the Notice of the AGM and other statutory reports, in compliance with SEBI Listing Regulations. The Annual Report is available on the company's website. Key dates include a cut-off date of August 5, 2026, for voting eligibility, with remote e-voting commencing on August 8, 2026, and concluding on August 10, 2026. The filing also lists the Board of Directors and Key Managerial Personnel.